RECOGNITION AT EUROPEAN INNOVATION COUNCIL’S INVESTOR DAY
We are delighted to announce that Dr. Niv Bachnoff, our Chief Scientific Officer, has won the First Prize for Best Presentation in the Biotech & Pharmaceuticals category at the European Innovation Council’s Investor Day on Healthcare, which took place in Lisbon in November, presenting Omnix Medical to Investors and fellow EIC H2020 champions and raising […]
STUDY: In Vitro and In Vivo Antimicrobial Activity of the Novel Peptide OMN6 against Multidrug-Resistant Acinetobacter baumannii
The rapid worldwide spread of antimicrobial resistance (AMR) underscores the significant need for the development of innovative treatments to fight multidrug-resistant bacteria. Our Scientists at Omnix Medical have published a study demonstrating the potent antimicrobial activity of the novel peptide OMN6 against a wide array of drug-resistant Acinetobacter baumannii. Results point to OMN6 as a novel antimicrobial […]
OMNIX MEDICAL ANNOUNCES THE ADDITION OF TWO NEW PEPTIDE FAMILIES – OMN50 AND OMN70
Omnix Medical is pleased to announce the addition of two new peptide families – OMN50 and OMN70. At Omnix, we are working hard to build our clinical pipeline with new peptide-based drugs that address broad unmet medical needs. Using Omnix drug discovery platform to screen a wide-ranging array of peptides originating from marine organisms, insects […]
OMNIX MEDICAL STARTS PHASE I CLINICAL TRIAL OF NOVEL ANTI-INFECTIVE; FIRST HEALTHY VOLUNTEERS DOSED
New mechanism of action (MoA) addressing global increase of antimicrobial resistance (AMR) burden and shortage of potent anti-infectives JERUSALEM, Israel, April 12, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced the initiation of a Dutch Phase I clinical trial with its lead compound OMN6. Since […]
OMNIX MEDICAL ADVANCES NOVEL ANTI-INFECTIVE PROGRAM INTO CLINICAL DEVELOPMENT
Entirely novel therapeutic principle to combat alarming worldwide rise of antimicrobial resistance (AMR) JERUSALEM, Israel, March 16, 2022 — Omnix Medical, a biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, today announced it received approval by Dutch authorities to initiate a Phase I clinical trial with its lead compound OMN6 in healthy […]
OMNIX MEDICAL CSO NAMED A BEAM ALLIANCE NATIONAL COORDINATOR
To encourage EU Member States to actively contribute to exchanges on AMR in the co-legislative process, the BEAM Alliance relies on a network of National Coordinators. The aim is to encourage every state to put in place their own plan to combat AMR, in particular by supporting innovation. Omnix Medical is pleased to share the work of […]
OMNIX EARNS GRANT AWARD FROM ISRAEL INNOVATION AUTHORITY
Omnix Medical is honored to have earned a recent grant award from the Israel Innovation Authority to support continued development of new and effective lifesaving drugs to combat the spread of antimicrobial resistance.
EUROPE’S ANTIBIOTIC INVESTMENTS STAGNATE AS RESISTANCE CRISIS LOOMS
By Jonathan Smith at Labiotech.eu Despite the urgent danger of antibiotic resistance, investments into European biotech antibiotic players have remained flat. However, growing regulatory and societal awareness could spell fresh investments in the coming years. Over the last decade, pressure has been mounting on healthcare systems as infectious microbes become harder and harder to fight […]
OMNIX MEDICAL RECEIVES NIH GRANT FOR THE DEVELOPMENT OF ITS NOVEL ANTIMICROBIAL PEPTIDE OMN6
Funding supports unique approach for fighting multi-drug resistant Acinetobacter baumannii (AB) Clinical trial preparations of OMN6 under way Jerusalem, Israel — Omnix Medical, a Jerusalem-based biopharmaceutical company developing next-generation anti-infectives for the treatment of life-threatening infections, has received a grant by the U.S. National Institutes of Health (NIH) for the development of its first-in-class antimicrobial peptide […]
OMN6 A NOVEL BIOENGINEERED PEPTIDE FOR THE TREATMENT OF MULTIDRUG RESISTANT GRAM NEGATIVE BACTERIA
New antimicrobial agents are urgently needed, especially to eliminate multidrug resistant Gram‐ negative bacteria that stand for most antibiotic‐resistant threats. In the following study, we present superior properties of an engineered antimicrobial peptide, OMN6, a 40‐amino acid cyclic peptide based on Cecropin A . . . READ ARTICLE PUBLISHED MARCH 23, 2021
This project has received funding from the European Union’s Horizon 2020 research and innovation programme under Grant Agreement No 966627 (OMNIX MEDICAL).